Molecule Details
InChIKeyWZDGZWOAQTVYBX-XOINTXKNSA-N
Compound NameTibolone
Canonical SMILESC#C[C@]1(O)CC[C@H]2[C@@H]3[C@H](C)CC4=C(CCC(=O)C4)[C@H]3CC[C@@]21C
Clinical Status Data-mined Candidate
Targets (Human+Pathogen)2
Pfam Stratification Cross-Family
Avg pChEMBL6.91
SourceChEMBL
2D Structure
2D structure
Activity Profile
DrugBank Annotations
DrugBank ID DB09070
Drug NameTibolone
CAS Number5630-53-5
Groups approved investigational
ATC Codes G03CX01
DescriptionTibolone is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha [L1874]. Tibolone (Livial, Org OD 14), produced by Organon (West Orange, NJ), is a synthetic steroid that poss...

Categories: Anabolic Agents Antineoplastic Agents, Hormonal Cardiovascular Agents Estrogen Receptor Modulators Estrogens Estrogens, Antiestrogens, and Estrogen Agonist-Antagonists Fused-Ring Compounds Genito Urinary System and Sex Hormones Hormone Antagonists Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Norpregnanes Norsteroids Sex Hormones and Modulators of the Genital System Steroids
Cross-references: ChEBI: 32223 CHEMBL2103774 ChemSpider: 392038 Drugs Product Database (DPD): 1251 D01639 PubChem:444008 PubChem:347827821 RxCUI: 38260 Wikipedia: Tibolone ZINC: ZINC000003812889
Target Activities (2)
Target Gene Organism Category Pfam pChEMBL Type Source
P31645 SLC6A4 Homo sapiens Human PF03491 PF00209 7.2 IC50 ChEMBL
P03372 ESR1 Homo sapiens Human PF12743 PF00104 PF02159 PF00105 6.6 IC50 ChEMBL
DrugBank Target Actions (7)
Target Gene Target Name Action Type
P02768 ALB Albumin binder carriers
P08842 STS Steryl-sulfatase inhibitor enzymes
P14060 HSD3B1 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 substrate enzymes
P26439 P26439 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2 substrate enzymes
P50225 SULT1A1 Sulfotransferase 1A1 substrate enzymes
P03372 ESR1 Estrogen receptor agonist targets
P03372 ESR1 Estrogen receptor antagonist targets